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In this study, we tested the hypothesis that donors with broadly cross-reactive HIV-1 neutralizing (BCN) sera are infected with viruses
encoding envelope glycoproteins (Envs) with unusual immunogenic properties. Cloned env genes were from samples of donors previously
identified as having BCN antibodies (BCN donors) and from other donors not known to have such antibodies (non-BCN donors). Neutralization
properties of viruses pseudotyped with BCN and non-BCN Envs were determined using BCN, non-BCN sera and broadly cross-neutralizing
monoclonal antibodies (Mabs). BCN sera neutralized with higher frequency and geometric mean titers than non-BCN sera. Viruses pseudotyped
with BCN Envs were mostly resistant to neutralization by anti-gp120 Mabs but tended to be more sensitive to the anti-gp41 Mabs, 2F5 and 4E10
than non-BCN Env-pseudotyped viruses. Sequence analysis of clones obtained from sequential samples of two BCN donors revealed respective
2F5 epitope mutations T662A and K665T. The K665T mutation evolved as the predominant genotype in the respective donor, consistent with an
escape mutation event. The A662T mutation reduced sensitivity to 4E10, as well as 2F5 and homologous sera, consistent with neutralization
escape mutation and targeting of the 2F5 epitope region by the serum. Our study suggests that viruses infecting these BCN donors encoded Envs
that may have been unusually competent for induction of antibodies against the membrane proximal epitope region (MPER) of gp41, and these
Envs may be useful vaccine components.
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The definition of immunogenic epitopes on the HIV-1
envelope glycoprotein (Env) that can induce broadly cross-
reactive neutralizing (BCN) antibodies remains an enigma.
Efforts to develop vaccines that induce BCN antibodies have
progressed slowly owing to HIV-1’s ability to elude the host0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Prevention, Shanghai, China.immune responses. The number and positioning of large
clusters of N-linked glycan moieties and masking of conserved
epitopes in the receptor and coreceptor-binding sites and in
gp41 limit access of neutralizing antibodies to potentially
important epitopes on the viral Env (Kwong et al., 2002;
Labrijn et al., 2003; Scanlan et al., 2002, 2003; Wei et al.,
2003; Zwick et al., 2001). Additionally, HIV-1 utilizes
antigenic variation and mimicry of self antigens to thwart
production of effective neutralizing antibodies (Haynes et al.,
2005; Moore et al., 2001; Nabel, 2005).
Despite HIV’s immune evasion tactics, reported findings of
BCN antibodies in sera of infected patients indicate that HIV-1
strains share cross-reactive neutralization epitopes and humans06) 36 – 51
www.e
Table 1
Characteristics of BCN and non-BCN donors and envelope pseudotypes
Donors Env
subtype
Origin Sampling
year
Luciferase
unitsa
R2 B North
America
1989 539,957
BCN VI 423 B Europe 1990 60,102
VI 843 B Europe 1993 99,690
14/00/4 F1 Africa 1994 3,056,071
VI 1249 CRF01_AE Asia 1994 238,477
24/00/4 CRF02_AG Africa 1994 1,343,945
VI 1793 CRF06_cpx Africa 1996 769,105
Non-BCN 92RW20.5 A Africa 1992 154,846
NYU1423 A Africa 2000 1,124,994
VI 1273 B Europe 1996 343,540
VI 1399 B Europe 1994 1,483,216
MACS4 B North
America
1994 1,594,686
GXC-14 C Asia N/A 1,527,941
Z2Z6 D Africa 1985 693,122
93BR029 F1 South
America
1993 142,795
GXE-14 CRF01_AE Asia N/A 652,103
NYU1026 CRF02_AG Africa 2002 683,004
CA1 CRF11_cpx Africa 1993 4,225,479
GenBank accession numbers are as follows: VI 1793: DQ313254; VI 843:
DQ313250; VI 423: DQ313249; 14/00/4: DQ313239; 24/00/4: DQ313242;VI
1249: DQ313251; NYU1423: DQ313248; VI 1273: DQ313252; VI 1399:
DQ313253; MACS4 (4/116): DQ313246; NYU1026: DQ313247; 93BR029:
AF005495; CA1: AJ277823. Sequences which have been submitted previously
are: R2: AF128126; GXC-14: AY217546; GXE-14: AY217545; and Z2Z6:
K03458.
a Values indicate luminescence reading in HOS CD4+CCR5+ cells infected
with undiluted viruses pseudotyped with the indicated Env, except for VI 1249
and Z2Z6, which were tested for infectivity in HOS CD4+CXCR4+.
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2000; Donners et al., 2002; Nyambi et al., 1996; Quinnan et al.,
1999; Vujcic and Quinnan, 1995; Zhang et al., 1999).
Moreover, a number of cross-reactive neutralization epitopes
are targeted by monoclonal antibodies (Mabs) isolated from
infected patients (Burton et al., 1994; Moulard et al., 2002;
Muster et al., 1994; Purtscher et al., 1994; Scanlan et al., 2003;
Zhang et al., 2004; Zwick et al., 2001). The Mab IgG1 b12 and
the antibody fragments (Fab) X5, 17b and 48d neutralize some
HIV-1 isolates by targeting epitopes in the CD4 and coreceptor
binding sites, respectively (Burton et al., 1994; Kwong et al.,
2002; Labrijn et al., 2003; Moulard et al., 2002; Thali et al.,
1991; Wyatt et al., 1995). The only potent broadly cross-
reactive Mab reported to target a heavily glycosylated region of
gp120 is 2G12 (Sanders et al., 2002; Scanlan et al., 2002,
2003). The Mab 447-52d recognizes a 14-mer epitope,
KRIHIGPGRAFYTT, that forms a conserved type II h turn
motif at the tip of the V3 loop of X4 and R5 isolates (Kwong,
2004; Sharon et al., 2003). The anti-gp41 Mabs 2F5 and 4E10
target highly conserved epitopes located near the C-terminal
end of the gp41 ectodomain (Cardoso et al., 2005; Haynes et
al., 2005; Ofek et al., 2004; Trkola et al., 1995; Zwick et al.,
2001, 2004). Most recently, the novel antibodies, m14 and
m18, which target the CD4bs and epitopes between the CD4
and coreceptor binding sites, respectively, have been shown to
neutralize some primary isolates (Zhang et al., 2003, 2004).
Studies using combinations of some of these Mabs, including
b12, 2G12, F105, 4E10 and 2F5, have resulted in protection
against intravenous and/or mucosal simian–human immuno-
deficiency virus (SHIV) challenge in monkeys (Li et al., 1997,
1998; Ruprecht et al., 2003). In addition, 2F5 and/or 4E10 plus
2G12 immunotherapy have resulted in reduced viremia in
established HIV-1 infection or delay of HIV-1 rebound in
individuals undergoing interrupted antiretroviral treatment
(ART) (Stiegler et al., 2002; Trkola et al., 2005). Epitopes
targeted by certain of these Mabs may be candidates for
induction of BCN antibody responses.
Despite knowledge of the target epitopes of most of these
potent antibodies, construction of vaccines that can induce
broad cross-reactive antibodies has been a difficult challenge
(Burton et al., 2004b; McGaughey et al., 2004; Muster et al.,
1994; Nabel, 2005; Pantophlet and Burton, 2003; Saphire et al.,
2003; Selvarajah et al., 2005). Nonetheless, immunization of
small animals and macaques with a CD4-independent Env
immunogen designated as strain R2, isolated from a donor
whose serum possesses BCN activity (de Souza et al., 1997;
Quinnan et al., 1999; Vujcic and Quinnan, 1995; Zhang et al.,
2002), resulted in induction of antibodies that neutralized some
heterologous primary HIV-1 strains (Dong et al., 2003;
Quinnan et al., 2005). The titer of neutralizing antibodies
correlated with protection of macaques against intravenous
challenge with heterologous SHIVDH12R, Clone 7 (Quinnan et
al., 2005). The experience with R2 suggests that Envs from
donors with HIV-1 BCN antibodies may be useful for induction
of BCN antibodies in vaccinated animals or people.
Sera collected from approximately 10% of donors enrolled
in cohort studies conducted at the Institute of TropicalMedicine (ITM), Belgium were reported to possess BCN
activity (Beirnaert et al., 2000; Donners et al., 2002). BCN
activity was defined as neutralization of three key primary
isolates, namely, MN (subtype B), VI 525 (mixture of two
viruses of Env subtypes A and G) and CA 9 (Group O)
(Beirnaert et al., 2000) or strains CA 4 (subtype F), CA 13
(subtype H) and VI 686 (group O) (Donners et al., 2002). The
BCN sera derived from donors infected with diverse HIV-1
subtypes neutralized either set of key isolates as well as
panels of HIV-1 strains of multiple subtypes. The donors
included in the ITM studies were European and Africans and
were infected with diverse subtypes of HIV-1. The donors
found to have BCN antibodies were mostly African females
infected with diverse subtypes (Table 1) (Beirnaert et al.,
2000; Donners et al., 2002; Nyambi et al., 2000).
We hypothesized that those HIV-1 patients from the ITM
cohorts with BCN antibodies may harbor virus strains that
encode Env proteins that are exceptionally competent for
induction of BCN antibodies and that the reasons for the broad
immunogenicity of the Envs would be reflected in neutraliza-
tion characteristics of the Envs. To test our hypothesis, we
cloned env genes and characterized the neutralization proper-
ties of the encoded Envs from six donors defined as having
BCN antibodies (BCN donors) in the ITM studies and from 11
donors not characterized as having BCN antibodies (non-BCN
F. Cham et al. / Virology 347 (2006) 36–5138donors). The Env subtypes of viruses infecting BCN and non-
BCN patients belonged to HIV-1 subtypes A, B, C, D, F,
CRF01_AE, CRF02_AG, CRF06_cpx and CRF11_cpx. The
neutralization characteristics were determined using viruses
pseudotyped with cloned Envs. Neutralization was tested using
autologous sera, heterologous sera, soluble CD4 (sCD4) and a
panel of Mabs directed against conformation-dependent epi-
topes in gp120 and gp41. Our results suggest that certain of
these Env may have unusual properties associated with
neutralizing antibody responses to important membrane prox-
imal neutralization epitopes in the gp41 ectodomain.
Results
Infectivity and serum neutralization of viruses pseudotyped
with functional HIV-1 env genes
For each donor, approximately 10% of the Env clones
obtained mediated infection of Human Osteosarcoma (HOS)
cells expressing CD4 and either CCR5 or CXCR4, as measured
by luciferase activity. Among those that were functional, the
majority had similar levels of infectivity (data not shown), and a
clone with the highest apparent infectivity was selected for
further characterization. Characteristics of Env clones obtained
in this study are shown in Table 1. The Envs generated in this
study were CCR5-tropic, except for Z2Z6 and VI 1249, which
displayed dual-tropism for CCR5 and CXCR4 (Quinnan et al.,
1999). The luciferase units detected in CCR5+ and CXCR4+
HOS cells infected with undiluted virus pseudotyped with Env
Z2Z6 were 113, 379 and 693,122 respectively. The luciferase
units detected in CCR5+ and CXCR4+ HOS cells infected with
undiluted virus pseudotyped with VI 1249 were 85,000 and
238,477 LU respectively. None of the BCN or non-BCN Envs
mediated CD4-independent infection (data not shown).
Viruses pseudotyped with R2 Env and Envs from 6 BCN and
11 non-BCN donors, as described in Table 1, were tested for
neutralization by BCN and non-BCN sera previously identified
in studies conducted by Beirnaert et al. (2000) and Donners et al.
(2002). The BCN sera were collected 6 months after the sample
used in the generation of the BCN envelope clones, except in the
cases of Envs 24/00/4 and VI 423, for which the sera
corresponded to the same times of the PBMC collections. Sera
corresponding to the specific non-BCN Env donors used in this
study were unavailable. However, the non-BCN sera used in this
study were selected from a panel of sera classified based on low-
to-absent neutralizing potency against the aforementioned
primary isolates CA 4, CA 13 and VI 686 (Donners et al.,
2002). As shown in Fig. 1A, the BCN sera neutralized virus
pseudotyped with the R2 Env and each of the BCN Envs at titers
ranging from 1:8 to 1:2048 (overall geometric mean titer (GMT)
of the BCN sera to neutralize BCNEnvs = 1:110). The non-BCN
sera neutralized the BCN Envs at titers ranging from 1:4 to
1:1024. Viruses pseudotyped with Env 14/00/4 and VI 423 were
neutralized significantly more by BCN than non-BCN sera. The
geometric mean titers were higher against viruses pseudotypes
with R2 Env and BCN Envs 24/00/4, VI 1793, VI 843 and VI
1249 for the BCN than the non-BCN sera, although statisticalsignificance of these differences was not demonstrated. As
shown in Fig. 1B, the BCN and non-BCN sera neutralized
viruses pseudotyped with non-BCN Envs at titers ranging from
1:8 to 1:1024. Among the non-BCN Envs, virus pseudotyped
with Envs VI 1273, MACS#4, CA1 and NYU1423 was
neutralized significantly more by BCN than non-BCN sera.
Viruses pseudotyped with other non-BCN Envs were also
neutralized more by BCN than non-BCN sera, although these
differences were not statistically significant. Two non-BCN
Envs, notably CA1 and 93BR029, displayed low specificity and
were neutralized at titers1024 by all the BCN sera and by four
non-BCN sera (VI1401, VI 1400, VI 0998 and VI1295). The
low specificity of the CA1 virus to neutralization by diverse
HIV-1 sera was previously observed (Nyambi et al., 1996).
Small sample sizes may have limited our ability to
determine statistically significant differences between neutral-
ization of some pseudotyped viruses by BCN and non-BCN
sera. To further test the consistency of trends for greater
neutralization by the BCN and non-BCN sera, we compared
GMTs for BCN and non-BCN sera using paired Student’s t
test. The overall GMTs of BCN and non-BCN sera against
viruses pseudotyped with BCN Envs were 1:110 and 1:38,
respectively (P = 0.006). The overall GMTs of BCN and non-
BCN sera against viruses pseudotyped with non-BCN Envs
were 1:115 and 1:42, respectively (P = 0.0007). The overall
GMTs for neutralization of viruses pseudotyped with the BCN
and non-BCN Envs by BCN and non-BCN sera were 1:113
and 1:41, respectively (P = 5.14  106). The differences in
titers of BCN and non-BCN sera remained significant if titers
against the homologous pseudotyped viruses were not included
in the comparisons (P = 1.28  105).
Neutralization of viruses pseudotyped with BCN Envs 24/
00/4 and VI 423 by contemporaneous serum was observed.
This observation could reflect that Env clones were obtained
from genomic proviral DNA, instead of plasma viral RNA. For
that reason, the Env clones may represent historically relevant
envelope glycoproteins, but not Envs present on viruses
actually being produced at time of sampling.
Among the BCN sera, the one with the lowest overall GMT
(1:42) was VI 1249/8. An earlier serum from this donor was
previously classified as having lower levels of cross-reactive
neutralizing activity (Beirnaert et al., 2000). Moreover, this
donor was infected with a subtype CRF01_AE strain, and cross-
reactive neutralization of non-CRF01_AE strains by such sera is
expected to be low (Mascola et al., 1994; Zhang et al., 2002).
Comparative neutralization properties of BCN and non-BCN
pseudotypes by Mabs and sCD4
To determine whether BCN Envs displayed greater compar-
ative sensitivity to neutralization at particular epitopes than non-
BCN Envs, we compared neutralization of viruses pseudotyped
with BCN and non-BCN Envs using two-domain sCD4 and a
panel of cross-neutralizing Mabs, as illustrated in Fig. 2. Fab
19b, 4KG5, Z13 and 4.8d neutralized the BCN and non-BCN
Env-pseudotyped viruses infrequently, and results for those
Mabs are not shown. The R2-pseudotyped virus was neutralized
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were of comparable susceptibility to neutralization by sCD4 and
the gp120 Mabs X5, IgG1b12, 17b, 2G12 and 447-52d as the
non-BCN Envs (Fig. 2). As was the case for serum neutraliza-
tion, the non-BCN Envs CA1 and 93BR029 were always
sensitive to neutralization by these gp120 Mabs. The sensitivity
of these two non-BCN Envs to neutralization by both human
sera and gp120 Mabs is consistent with the interpretation that
these two clones possessed a global neutralization sensitivity
phenotype (Donners et al., 2003; Nyambi et al., 1996).
Viruses pseudotyped with Envs from five of the six BCN
donors exhibited sensitivity to neutralization by the anti-gp41
Mabs, 2F5 and 4E10. BCN Envs were neutralized by 2F5 at
ID50 ranging from 0.2 to 3 Ag/ml (Fig. 2). The R2 Env was also
sensitive to 2F5 neutralization, consistent with a previous
report (Zhang et al., 2002). Virus pseudotyped with BCN Env,
VI 843, was resistant to neutralization by Mab 2F5 at 50 Ag/ml.
The Mab 2F5 neutralized viruses pseudotyped with the non-
BCN Envs at ID50 ranging from 0.39 to 25 Ag/ml. Most of the
viruses pseudotyped with the BCN Envs were also sensitive to
neutralization by Mab 4E10, with ID50 ranging from 0.2–
<6.25 Ag/ml. Env VI 843, which was resistant to 2F5,
displayed intermediate resistance to neutralization by Mab
4E10, with ID50 = 12.5 Ag/ml. The sensitivity to neutralization
by 4E10 of viruses pseudotyped with the non-BCN Envs
ranged from 1.56 to 25 Ag/ml. One of the globally sensitive
non-BCN Env 93BR029 was the most sensitive of the non-
BCN Envs to neutralization by the gp41 Mabs, while the other,
CA1, displayed intermediate resistance to the gp41 Mabs.
Two BCN Envs that were sensitive to neutralization by Mab
2F5, 14/00/4 and 24/00/4, respectively were derived from
samples of two donors with the most potent BCN sera as
defined by Beirnaert et al. (2000). These two Envs were
resistant to all Mabs targeting gp120 epitopes, and 24/00/4 was
also resistant to sCD4 (Fig. 2). Likewise, samples obtained 6
months after the sample that yielded Env clones 14/00/4 and
24/00/4 were used for production of additional Env clones. The
sensitivity of viruses pseudotyped with the early and late Envs
from these donors to Mabs 2F5 and 4E10 is shown in Figs. 3A
and 4A. Of two late clones from donor 14/00, clone 14/00/8-33
was sensitive to neutralization by Mabs 2F5 and 4E10, while
14/00/8-83 was relatively resistant to both Mabs (2F5 ID50 =
0.01 vs. >12.5Ag/ml, 4E10 ID50 = 0.2 vs. 7.8 Ag/ml; Fig. 3A).
Of three Env clones obtained from the late sample from donor
24/00, clones 24/00/8-46 and 24/00/8-275 were sensitive to
neutralization by Mab 2F5, similar to Env 24/00/4, while the
late clone 24/00/8-258 was relatively resistant (Fig. 4A). The
early and late Env clones from this donor displayed similar
sensitivity to Mab 4E10. The finding that late clones from each
of these donors were resistant to 2F5 raised the possibility that
neutralization escape mutants had emerged in each donor as a
result of selection by antibodies in their serum. The variable
sensitivity of Env clones from these two donors to neutraliza-
tion by these Mabs did not result from virus cultivation since
early and late Env clones were generated from uncultured
PBMC samples (Beaumont et al., 2004; Schuitemaker and
Kootstra, 2005).Amino acid sequence variability within the 2F5 and 4E10
epitopes
We analyzed the amino acid sequences of the region of gp41
that includes the epitopes targeted by Mabs 2F5 and 4E10, as
shown in Table 2. The 2F5 epitope has been reported to include
the 13 amino acid sequence ELLELDKWASLWN, extending
from residue 659 through residue 671 of gp160. In particular, the
residues DKW at positions 664–666 have been reported to be
critical for Mab 2F5 binding (Barbato et al., 2003; Binley et al.,
2004; Li et al., 2005; Ofek et al., 2004; Zwick et al., 2004, 2005).
Substitutions within the DKW tripeptide were observed only in
the two BCN Env clones, 24/00/8-258 and VI 843, that were
resistant to neutralization by Mab 2F5 at 50 Ag/ml. These
substitutions were K665T in 24/00/8-258 and D664G in VI 843.
Two other substitutions, A667D and N671S in VI 843, may have
contributed to 2F5 resistance. The only 2F5 epitope substitution
that distinguished the Env clones that were highly sensitive to
neutralization by Mab 2F5, 14/00/4 and 14/00/8-33, from the
Env that was more resistant to neutralization, 14/00/8-83, was
A662T. Commonly observed substitutions in other BCN Env
that apparently did not contribute to resistance to neutralization
by Mab 2F5 included E659D and E662A (Cardoso et al., 2005;
Trkola et al., 1995; Zwick et al., 2005). These latter two
substitutions were also commonly observed in the non-BCN
Envs. Besides these, the only substitutions observed in the 2F5
epitope sequence were E662S and N671S in Env CA1 and
S668G in Env NYU1423. Viruses pseudotyped with these two
Env were intermediately resistant and resistant to neutralization
by Mab 2F5, respectively (ID50 of 12.5 and 25 Ag/ml) (Fig. 2).
The 4E10 epitope has been defined as the six-amino-acid-
peptide NWFDIT, extending from amino acid residue 671
through 676 of gp160. Two common substitutions, D674N and
T676S, within the 4E10 epitope did not appear to correlate with
neutralization resistance (Binley et al., 2004; Cardoso et al.,
2005; Zwick et al., 2001, 2005). The BCN Env clone VI 843,
which was intermediately resistant to neutralization by Mab
4E10, had the additional substitution N671S. Other substitu-
tions in the non-BCN Envs that may account for moderate
resistance to neutralization by Mab 4E10 were N671S and
D674E in Env CA1 and D674S in Env MACS4. No amino acid
substitutions were apparent within the 4E10 epitope sequence of
Envs NYU1026 and NYU1423 that might account for the
relative resistance of those Envs to neutralization by Mab 4E10.
No mutation in the 4E10 epitope sequence distinguished the
donor 14/00 Env clones that were highly sensitive to
neutralization by Mab 4E10, 14/00/4 and 14/00/8-33 (ID50 =
0.2 Ag/ml) from the clone that was less sensitive, 14/00/8-83
(ID50 = 7.8 Ag/ml) (Fig 3A).
Contribution of the A662T mutation in the 14/00/8-83 Env to
resistance to neutralization by Mabs 2F5 and 4E10
The mutations T662A in 14/00/8-83 and K665T in 24/00/
8-258 are of particular interest because of their potential
contributions to the moderate and full resistance to neutral-
ization of those clones to Mab 2F5. The 662T sequence in the
Fig. 1. Comparative neutralization of viruses pseudotyped with Envs of BCN (A) and non-BCN (B) donors by sera from BCN n and non-BCN donors g. Assays
were performed in triplicate. Results are from single experiments or are averages from two experiments in a few cases. Neutralization titers were defined as the
highest serum dilution that resulted in greater than or equal to 50% inhibition of luciferase activity. Due to sample limitation, pseudotyped viruses VI 843, VI 1249,
VI 1793, 93BR20.9 and NYU1026 were not tested for neutralization by serum from donor VI 0747. Likewise, serum from donor VI 1071 was not tested against
pseudotyped viruses VI 843, 24/00/4, VI 1249, VI 1793, 93BR029, CA1, NYU 1423 and NYU1026. The horizontal dashed lines demonstrate the geometric mean
titers of neutralization of each Env by the panel of BCN and non-BCN sera. P values on charts are results of two-tailed Student’s t tests comparing geometric
means of BCN and non-BCN serum titers. The overall GMTs for neutralization of viruses pseudotyped with the BCN and non-BCN Envs by BCN and non-BCN
sera were 1:113 and 1:41, respectively ( P = 5.14  106 by paired Student’s t test), comparing the geometric metric means of BCN and non-BCN sera against
each virus.
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other sequence with this substitution in the HIV and GenBank
databases (HIV-1 ARMA037; accession # AY037277) (Carr et
al., 2001). To investigate whether this unusual mutation confers
susceptibility to Mab 2F5 neutralization, we used site-directed
mutagenesis to introduce the T662A mutation into clone 14/00/
4 and to introduce the reverse mutation (A662T) into the non-
BCN clones, NYU1026 and NYU1423, which were sensitive
and resistant to Mab 2F5 neutralization, respectively. Theeffects of these mutations on sensitivity to neutralization by
Mabs 2F5 and 4E10 are shown in Fig. 3B. The alanine
substitution into Env 14/00/4 changed it from highly sensitive
to relatively resistant to neutralization by Mabs 2F5 (ID50 =
0.45 vs. 6.25 Ag/ml) and 4E10 (ID50 = 0.9 vs. 9.34 Ag/ml).
Introduction of threonine at the same position of Env
NYU1026 had the reverse effect on sensitivity to neutralization
by Mabs 2F5 (ID50 = 3.13 vs. 0.31 Ag/ml) and 4E10 (ID50 =
10.41 vs. 0.78 Ag/ml). The magnitude of the effects of these
Fig. 2. Neutralization of viruses pseudotyped with BCN and non-BCN Envs by
Mabs and sCD4. Results are shown for viruses pseudotyped with the BCN and
non-BCN Envs as follows: R2: q 14/00/4: g; 24/00/4: o VI 423: r; VI 843: 0;
VI 1249: n; and VI 1793: >; all non-BCN Env are shown as .. Neutralization
assays were performed in triplicate, and results shown are geometric means of
two independent experiments. Mabs were tested for neutralization in serial two-
fold dilutions. The 50% inhibitory dose (ID50) was defined as the lowest Mab
concentration that resulted in greater than or equal to 50% inhibition of viral
infectivity.
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relative differences in sensitivity to neutralization by Mabs 2F5
and 4E10 of the Env clones 14/00/4 and 14/00/8-33 compared
to 14/00/8-83. Introduction of threonine at the same position of
Env NYU1423 caused a small but consistent increase in
sensitivity to neutralization by Mab 2F5 (ID50 = 17.7 vs. 10.4
Ag/ml) and no significant change in sensitivity to neutralization
by Mab 4E10. The results demonstrated that the presence of
threonine at residue 662 is associated with increased sensitivityFig. 3. Effects of Thr 662 on sensitivity to neutralization by gp41 Mabs and polyclon
and late 14/00/8-33 (q) and 14/00/8-83 (g), Env clones from donors 14/00 to neutral
obtained in the presence of Mab compared to medium. (B) Comparative effects of T6
pseudotyped with the 14/00/4, NYU1026 and NYU1423 Envs were compared for
construct the 14/00/4 (A662), NYU1026 (T662) and NYU1423 (T662) mutant Envs
pseudotyped with Envs having T662 are shown as g. (C) Comparative neutralization
BCN and non-BCN polyclonal serum. The ID50 for each serum was determined by li
of virus pseudotyped with 14/00/4 (T662) and 14/00/4 (A662) by each polyclonalto neutralization by both of these Mabs to an extent that
depends on the particular Env evaluated.
Thr 662 significantly contributes to the broad
cross-neutralizing activity of BCN serum from donor 14/00
To further test the possible relationship of Thr 662 to
induction of antibodies against theMPER of gp41, we compared
sensitivity of virus pseudotyped with Envs 14/00/4 and 14/00/4
T662A mutant to neutralization by BCN (14/00/8, 24/00/8,
HNS2) and non-BCN (VI 1077, VI 1295, VI 1400) sera. As
illustrated in Fig. 3C, the T662A mutation resulted in 211 and
27-fold resistance to neutralization by serum 14/00/8 and 24/00/
8, respectively. In comparison, the mutation had a lesser effect
on neutralization by HNS2 serum and the non-BCN sera VI
1295, VI 1400 and VI 1077, with relative resistance of the
mutant ranging from 1- to 10-fold. Thus, reduced sensitivity of
the 14/00/4 T662Amutant to neutralization by the BCN sera 14/
00/8 and 24/00/8, but not by the non-BCN sera, supports the
possibility that these particular BCN sera may have relatively
high neutralizing activity directed against the MPER of gp41.
Contribution of the K665T mutation in the 24/00/8-258 Env to
resistance to neutralization by Mab 2F5
Previous studies have reported that a K665Nmutation results
in poor binding and resistance to 2F5 neutralization of HIV-1
primary isolates (Conley et al., 1994b; Stiegler et al., 2001). Of
three late envelope clones derived from donor 24/00, one (24/00/
8-258) was resistant to neutralization byMabs 2F5 (Fig. 4A) and
displayed a single mutation within the 2F5 epitope sequence,
K665T. To confirm the relevance of this mutation to neutrali-
zation by 2F5, we introduced the K665T point mutation into Env
24/00/4. This mutation caused resistance to 2F5 but had no effect
on 4E10 sensitivity (Fig. 4B).
Quasispecies variations in the 2F5 and 4E10 epitopes of BCN
donors 14/00 and 24/00
To further evaluate whether the late Envs 14/00/8-83 and 24/
00/8-258, which were relatively resistant to neutralization by
Mab 2F5, represented emergence of neutralization-resistant
escape variants in these donors, we examined quasispecies
variation at the 2F5 and 4E10 epitopes in each of these donors.
For this purpose, using uncultured PBMC genomic DNA as
template for PCR, we cloned and analyzed amino acid sequences
of the MPER of gp41 from early and late PBMC samples from
these two donors. Results of these analyses are shown in Tables 3
and 4. In donor 14/00, 9 of 10 early and all the late gp41 clonesal serum. (A) Variable sensitivity of viruses pseudotyped with early 14/00/4 (.)
ization by Mabs 2F5 and 4E10. Relative infectivity is the ratio of luciferase units
62 and A662 on sensitivity to neutralization by the Mabs 2F5 and 4E10. Viruses
neutralization by Mabs 2F5 and 4E10. Site-directed mutagenesis was used to
. Viruses pseudotyped with the Envs having A662 are shown as n, and viruses
of virus pseudotyped with 14/00/4 (T662) (g) and 14/00/4 (A662) (n) Envs by
near regression using Excel. Numbers above each bar are the differences in ID50
serum.
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(Table 3). However, in donor 24/00, 8 of 11 early, but only 3 of
10 late gp41 clones, were found to have the neutralization-
sensitive 665 K sequence (Table 4). These results indicate thatneutralization-resistant variants represented by clone 24/00/8-
258 had emerged as the dominant populations in this donor,
consistent with the emergence of neutralization escape mutants.
However, absence of the 662A sequence in clones from donor
Fig. 4. Effects of the K665Tmutation in Env clones of donor 2400 to neutralization byMabs 2F5 and 4E10. (A) Variable sensitivity of early 24/00/4 (.) and late 24/00/
8-46 (q), 24/00/8-275 (>) and 24/00/8-258 (g) Envs clones from donors 24/00 to neutralization by Mabs 2F5 and 4E10. Viruses pseudotyped with these Envs were
tested for neutralization by the twoMabs. Each result shown is from one experiment and is essentially the same as those from two replicate experiments. All experiments
were performed in triplicate. (B) The K665Tmutation in Env 24/00/8 determines resistance to neutralization byMab 2F5. Viruses pseudotyped with the 24/00/4 (K665)
(n) and 24/00/4 (T665) (g) Env were tested for neutralization by the Mabs 2F5 and 4E10. Assays were carried out in triplicate, and results shown are averages of two
independent experiments.
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emerged through escape mutation. Additional evidence of
escape might have been observed if analyses had included
sequences of plasma viral RNA or later samples from the donor.Table 2
Amino acid sequences of the gp41 regions comprising the 2F5 and 4E10 epitopes
a The 2F5 epitope sequence, as described by Barbato et al. (2003), is shown as ho
epitope sequence, as described by Zwick et al. (2001), is shown as homologous
sequences are decorated with shaded boxes.
b For 2F5, strains were considered to be sensitive (S), intermediate (I) or resistant (
strains were considered to be sensitive (S), intermediately resistant (I) or resistant (
c gp160 amino acids sequences retrieved from the HIV database (http://www.hivDiscussion
Neutralizing antibodies are commonly required for vac-
cine-induced protection against viral infections and are likelyof functional env clones from BCN and non-BCN donors
mologous to the 13-mer ELLELDKWASLWN (Barbato et al., 2003). The 4E10
to the six-mer NWFDIT (Zwick et al., 2001). Residues differing from those
R) if their ID
50
were 3.13, >3.13–12.5 or 25 Ag/ml, respectively. For 4E10,
R) if the ID
50
were 6.25, >6.25–12.5, or >12.5 Ag/ml, respectively.
.lanl.gov).
Table 3
Quasispecies variations in the 2F5 and 4E10 epitopes of the early and late env clones from BCN donor 14/00a
a Amino acid sequences corresponding to the epitope regions defined in Table 2 inferred from nucleotide sequences of cloned gp41 coding segments. Decorations
indicate residues that vary from the sequence of the full-length 14/00/4 Env clone. Clones 14/00/4, 14/00/8-33 and 14/00/8-83 are functional, full-length Env clones;
the remaining clones consist of gp41 sequences only. GenBank accession numbers for clones 14/00/8-33 and 14/00/8-83 are DQ313240 and DQ313241,
respectively.
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infection (Burton et al., 2004a, 2004b; Li et al., 2005;
Mascola et al., 2005; Moore and Burton, 2004; Quinnan,
1997). Occasionally, patients develop neutralizing antibody
responses that are highly cross-reactive. In this study, we
tested the possibility that Envs from such donors possess
neutralization epitope properties that are related to their BCN
antibody responses (Beirnaert et al., 2000, 2001; Donners et
al., 2002; Nyambi et al., 1996; Quinnan et al., 1999, 2005;
Zhang et al., 1999, 2002).
The neutralization-sensitive, CD4-independent R2 Env
derived from the donor of the Human Neutralizing Serum 2
(HNS2) was a paradigm in our study (Quinnan et al., 1999;
Vujcic and Quinnan, 1995; Zhang et al., 2002). The capacity ofTable 4
Quasispecies variations in the 2F5 and 4E10 epitopes of the early and late env clo
a Amino acid sequences corresponding to the epitope regions defined in Table 2 in
indicate residues that vary from the sequence of the full-length 24/00/4 Env clone. G
are DQ313243, DQ313245 and DQ313244, respectively.HIV-1 to mediate CD4-independent infection maybe associated
with enhanced capacity to induce neutralizing antibodies
(Dong et al., 2003; Edwards et al., 2001; Endres et al., 1996;
Hoxie et al., 1998; Quinnan et al., 2005; Zwick et al., 2003).
However, the BCN Envs obtained in the present study could
not mediate CD4-independent infection, causing us to examine
whether other conserved Env characteristics may have been
relevant to the induction of BCN antibodies in the sera from
these donors.
We conducted studies to examine the neutralizing activity
of sera from the BCN donors previously identified in ITM
studies. These previous studies were conducted using
replicating primary viruses and peripheral blood mononuclear
cells (PBMC) as indicator cells. Their results demonstratednes from BCN donor 24/00a
ferred from nucleotide sequences of cloned gp41 coding segments. Decorations
enBank accession numbers for clones 24/00/8-46, 24/00/8-275 and 24/00/8-258
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non-BCN donors. In the present study, assays were conducted
using pseudotyped viruses and Human Osteosarcoma (HOS)
cells as indicator cells. Pseudotyped virus assays in cell lines
tend to be more sensitive for detection of low serum
neutralizing activity than PBMC-based assays. This difference
may account for greater well-to-well precision of the
pseudotype virus assays versus assays that depend upon
multiple cycles of replication of primary viruses. Additionally,
cloned viruses may be more sensitive to neutralization than
parental uncloned viruses (Binley et al., 2004; Dong et al.,
2003; Li et al., 2005; Mascola et al., 2005; Quinnan et al.,
1998; Zhang et al., 1999). Most importantly, we did not have
available pseudotype viruses representative of all the viruses
used in the ITM studies, particularly the group O virus.
Notwithstanding, the BCN sera neutralized all the primary
Env-pseudotyped viruses, while non-BCN sera all failed to
neutralize one or more strains tested. The overall geometric
mean titers of the BCN sera were also higher than those of
the non-BCN sera. Thus, our serum neutralization results
generally confirmed those reported previously (Beirnaert et
al., 2000; Donners et al., 2002).
Our pursuit of the possibility that characteristics of the
MPER of gp41 may distinguish BCN from non-BCN Envs was
based initially on observation that the BCN and non-BCN Envs
were not distinguished by sensitivities to anti-gp120 Mabs.
Rather, the majority of BCN Envs were neutralized at lower
concentrations of 2F5 and 4E10 than the non-BCN Envs and
than commonly reported for primary strains of HIV-1 (Binley
et al., 2004; Cardoso et al., 2005; Conley et al., 1994b; Li et al.,
2005; Muster et al., 1994; Parren et al., 1998; Stiegler et al.,
2001; Trkola et al., 1995, 1998). Two of the BCN donors 14/00
and 24/00 were selected for further study of this issue, based on
their having the most cross-reactive serum neutralizing
activities among the group as reported by Beirnaert et al. and
their Envs being among the most sensitive to neutralization by
2F5 and 4E10.
Env clones obtained from later time point samples of donor
14/00 and 24/00 showed evidence of neutralization escape
mutation. In both cases, late clones were obtained that were
significantly more resistant to neutralization by 2F5 than the
original Env clones. Sequence analyses of these clones revealed
2F5 epitope mutations potentially responsible for the resistance,
and site-directed mutagenesis of homologous and heterologous
Envs confirmed the roles of the mutations in determining
resistance to 2F5. Of note, the 2F5 epitope mutation in Env from
donor 14/00 also conferred resistance to 4E10. Quasispecies
analyses confirmed the emergence of the 2F5-resistant genotype
in donor 24/00, but not donor 14/00. However, the 2F5
resistance mutation in Env clone from donor 14/00 conferred
resistance to neutralization by sera from donor 14/00, providing
support for the possibility that it constituted a neutralization
escape mutation. It is possible that analyses of quasispecies
variation in plasma RNA or in later PBMC samples of donor
14/00 would reveal quasispecies variations typical of escape
mutation. We have not yet conducted studies to determine
whether quasispecies variation is more consistent overall with2F5 epitope escape mutation in our BCN donors than in non-
BCN donors. However, the evidence reported here is consistent
with that possibility.
Structural studies of synthetic oligopeptides bound by each
of these Mabs have been published (Barbato et al., 2003;
Cardoso et al., 2005; Ofek et al., 2004; Zwick et al., 2004).
However, attempts to induce neutralizing antibodies against
these epitopes using synthetic oligopeptides as immunogens
have been unsuccessful. The failure of induction of neutralizing
antibodies by synthetic peptide immunization suggests that the
sequence is constrained in the intact Env complex in a
conformation that is relevant to induction of antibody
responses. Neutralizing Mabs that target the MPER of gp41
are rare in infected individuals (Cardoso et al., 2005; Kang et
al., 2005; Nabel, 2005; Ofek et al., 2004; Rusert et al., 2005;
Zwick et al., 2001, 2004, 2005). Haynes et al. have noted that
the structure of HIV-1 neutralizing antibodies, all of which have
extended CDRH3 regions, is typical of auto antibodies and that
these Mabs cross-react with human antigens targeted by
autoimmune responses (Haynes et al., 2005; Nabel, 2005).
This cross-reactivity may explain the rarity of broadly cross-
reactive human Mabs against HIV-1. Our evidence indicating
that BCN donors 14/00 and 24/00 may have developed
neutralization escape mutation in this region is, therefore, of
interest. Moreover, the observations that the rare 662T sequence
in Env of donor 14/00 was specifically associated with very
high sensitivity to neutralization byMabs 2F5 and 4E10, but not
other Mabs, and to neutralization by homologous sera constitute
additional evidence of the structural complexity of this region of
gp41 and of the possibility that this Env may be exceptionally
competent for induction of anti-MPER neutralizing antibodies.
The strategy used to identify BCN donors is likely related to
the epitope specificity of the BCN antibodies in their sera. In
particular, the inclusion of a Group O isolate in the panel of key
isolates used by the ITM studies probably resulted in
identification of donors with antibodies directed against the
MPER of gp41 (Beirnaert et al., 2000; Donners et al., 2002).
Moreover, group O viruses are sensitive to neutralization by
Mabs 2F5 and 4E10, but not other humanMabs (Beirnaert et al.,
2001; Ferrantelli et al., 2004; Trkola et al., 1995). Additional
studies to evaluate the potential immunogenicity of the MPER
of gp41 in the 14/00/4 and 24/00/4 Envs should include more
extensive evaluation of quasispecies variation in the donors at
sequential time points, characterization of the epitope specific-
ity of neutralizing antibodies in their sera and evaluation of the
immunogenicity of the Envs.
Materials and methods
Human sera
Sera collected from six BCN and eight non-BCN donors
previously characterized in clinical cohort studies at the AIDS
Reference Center of the Institute of Tropical Medicine (ITM) in
Antwerp, Belgium were used in the present study (Beirnaert et
al., 2000; Donners et al., 2002). Five of the BCN sera, VI 423,
14/00/8, VI 843, 24/00/4 and VI 1793, were collected from
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(MN, VI 525 and CA 9) with high potency (set 1 of Beirnaert
et al.) and one (set 2: VI 1249/8) neutralized with moderate
potency. These sera were collected from 4 to 17 months after
those described by Beirnaert et al., except serum 14/00/8 which
was collected approximately 1 year before the previously
published serum. The serum of BCN donors 14/00 and 24/00
was the most potent of the set 1 sera in the Beirnaert study
(Beirnaert et al., 2000). The eight non-BCN sera used (VI
0744, VI 0747, VI 0998, VI 1071, VI 1077, VI 1295, VI 1400
and VI 1401) previously exhibited weak or absent neutraliza-
tion of the primary viruses CA 4, CA 13 and VI 686 (Donners
et al., 2002). Due to sample limitation, the non-BCN serum VI
1071 was not tested against four BCN Envs (VI 843, 24/00/4,
VI 1249 and VI 1793) and four non-BCN Envs (93BR029,
CA1, NYU 1423 and NYU1026). The reference reagent,
HNS2, was obtained from National Institute of Health AIDS
Research and Reference Reagent Program (ARRRP), as
contributed by Luba Vujcic and Gerald Quinnan. Sera were
heated at 56 -C for 30 min prior to use and stored at 20 -C.
Cloning of HIV-1 envelope genes
Cryopreserved PBMC were the source of HIV-1 proviral
DNA of six antiretroviral-therapy-naive HIV-1 BCN donors
(Table 1) and two non-BCN donors (VI 1399 and VI 1273).
Two separate PBMC samples from donor 14/00 and 24/00,
which had been obtained at 6-month intervals, were used as
sources of env genes. DNA extracts from co-cultured PBMC
of four HIV-1-infected donors participating in ongoing cohort
studies at the New York Veterans Administration Medical
Center, who had not been selected based on neutralizing
antibody status, were included as sources of non-BCN env.
These Env designations were CA1, NYU1026, NYU1423 and
93BR029 (Nadas et al., 2004; Nyambi et al., 1996; Zhong et
al., 2002, 2003; Zolla-Pazner et al., 2004). The Env clones
MACS#4; GXC-44, GXE-14 and Z2Z6 have been described
previously (Quinnan et al., 1998; Zhang et al., 1999). The
plasmid pSV392RW20.5 was obtained from ARRRP, as contrib-
uted by Feng Gao and Beatrice Hahn (Gao et al., 1996). The
previously cloned and characterized R2 Env clone was also
used (Quinnan et al., 1999; Zhang et al., 2002). Genetic
subtype, geographic origin, year of sample collection and
luminescence infectivity reading of virus pseudotyped with
each Env are shown in Table 1.
Envelope genes were synthesized by nested polymerase
chain reaction (PCR) using the high fidelity rTth DNA
polymerase (Applied Biosystems, Foster City, CA). For
template, genomic DNAwas extracted using the Qiagen Blood
and Tissue Kit (Qiagen Inc., Valencia, CA) from uncultured or
co-cultured PBMC from all donors. Primers used for the first
round PCR were based on either subtype B or on Group M
consensus sequences. The second round primers were based on
subtype B sequence. All primers used in the second round PCR
incorporated restriction enzyme recognition sites for use in
cloning. The primers used in the nested PCR were as follows:
first round primers: subtype B consensus sense (nt 5831–5883;primer location is according to HXB2 numbering): 5V-
ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAG-
CATCCAGGAAGTCAGCC-3V and antisense (nt 9035–8994):
5V-GTCATTGGTCTTAAAGGTACCTGAGGTCTGTCTG-
GAAAACCC-3V or group M consensus sense (nt 5954–5983):
5V-GGCTTAGGCATCTCCTATGGCAGGAAGAAG-3V and
antisense (nt 9088-9059): 5V-CCAGTCCCCCCTTTTCT-
TTTAAAAAGTGGC-3V; second round primers: sense (nt
5950–5986): 5V-AAAAGGCTTAGGCATCTCCTATGGCAG-
GAAGAAGCGG-3V and antisense (nt 8902–8868): 5V-
CTCGAGATACTGCTCCCACCCCATCTGCTGCTGGC-3V.
PCR products were visualized on a 0.7% agarose gel and
column-purified prior to restriction enzyme digestion and
cloning into the vector pSV7d (Quinnan et al., 1998). Env
genes of plasmids with correctly sized inserts were screened for
function, as described below.
Cell cultures
The Human Osteosarcoma (HOS) cell lines constitutively
expressing CD4 and coreceptors for HIV-1, CCR5 or CXCR4,
or coreceptors only, were obtained from the ARRRP, as
contributed by Nathaniel Landau. HOS cells were maintained
in Dulbecco’s minimal essential medium (DMEM) (GIBCO,
Grand Island, NY) supplemented with 10% fetal bovine serum,
l-glutamine and penicillin–streptomycin (GIBCO), Tylosin
(Sigma) and puromycin for maintenance of plasmid stability.
The 293T human embryonic kidney cell lines obtained from the
American Type Culture Collection (ATCC, Rockville MD;
catalog no. 11268) were maintained in Dulbecco’s minimal
essential medium (GIBCO) supplemented with 10% fetal bovine
serum, l-glutamine and penicillin–streptomycin (GIBCO).
Functional assays of HIV-1 envelope glycoprotein
The ability of cloned Envs to mediate infection of HOS
CD4+CCR5+ or HOS CD4+CXCR4+ cells was assessed using
pseudotyped viruses, as previously described (Quinnan et al.,
1998). Pseudotyped viruses were produced by calcium phos-
phate/HEPES buffer co-transfection (Promega, Madison WI) of
293T cells with pNL4-3.luc.E-R (obtained from the ARRRP as
contributed by Nathaniel Landau)- and pSV7d-env plasmid.
Eighteen hours after transfection, the media were replaced with
media supplemented with 0.1 mM sodium butyrate (Sigma), and
cells were propagated for an additional 24 h. Supernatant was
clarified by centrifugation at 16,000 rpm for 5 min at 4 -C,
sterilized by passage through 0.45 Am pore size filters
(Millipore, Bedford, MA) and used in infectivity assays (Zhang
et al., 1999, 2002). Briefly, two-fold serial dilutions of
pseudotyped virus preparation supernatant were added to 1–
2  104 HOS CD4+CCR5+ or CXCR4+ cells per well in
microtiter wells. The plates were incubated at 37 -C in 5% CO2
for 3 days then washed with phosphate-buffered saline and
lysed for 30 min with 15 Al of Luciferase Assay System cell
lysis buffer (Promega, Madison WI). Luciferase activity was
read using a MicroLumat Plus luminometer (Wallac, Gaithers-
burg MD). An individual well was considered positive if the
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negative control.
Sequencing and analyses of envelope gene clones
Sequencing was performed using a panel of forward and
reverse primers designed based on consensus HIV-1 sequences
in the Los Alamos National Laboratory HIV sequence database
(http://www.hiv.lanl.gov). Products of the sequencing reactions
were purified using the Performa DTR gel filtration cartridge
(Edge BioSystems, Gaithersburg, MD). Nucleotide sequencing
was performed using the di-deoxy cycle sequencing technique
on an Applied Systems Model 3100 Genetic Analyzer (Foster
City, CA). Sequence alignment was performed using the DNA
Star software package, according to the methods of Higgins and
Sharp (1988). Individual bases were assigned based on three or
more sequences, including sequences in the forward and reverse
directions. Uniqueness of sequences was assessed using the
National Center for Biotechnology Information (NCBI) website
(http://www.nbi.nlm.nih.gov) and the Los Alamos National
Laboratory HIV databases (http://www.hiv.lanl.gov). Amino
acid residue numbers are assigned throughout this report on the
basis of the sequence of the clone HXB2 (GenBank accession
number K03455).
Monoclonal antibodies
To characterize the neutralization phenotypes of the envelope
used in this study, we used a panel of 11 broadly cross-reactive
human monoclonal antibodies (Mabs) and two-domain sCD4.
The Mabs used in this study were b12, Z13 and 4KG5, kindly
provided by M.B. Zwick and D.R. Burton (Burton et al., 1994;
Zwick et al., 2001, 2003); 447-52d kindly provided by S. Zolla-
Pazner (Conley et al., 1994a; Kessler et al., 2003; Sharon et al.,
2003; Sharpe et al., 2004); X5 kindly provided by D. Dimitrov
(Darbha et al., 2004; Labrijn et al., 2003; Moulard et al., 2002);
two-domain sCD4 was a gift from Dr. C Broder (USUHS,
Bethesda, MD) (Garlick et al., 1990); 2F5, 4E10, 2G12, 17b,
19b and 48d (Calarese et al., 2003; Cardoso et al., 2005; Muster
et al., 1993; Ofek et al., 2004; Purtscher et al., 1994; Sanders et
al., 2002; Scanlan et al., 2002, 2003; Zwick et al., 2001; Moore
et al., 1994, 1995; Wyatt et al., 1995).
Neutralization assays
In this study, we used a pseudotyped reporter virus
neutralization assay, as described previously (Dong et al.,
2003; Quinnan et al., 2005; Zhang et al., 1999, 2002, 2004).
Briefly, neutralization assays were carried out in triplicate by
preincubation of 25 Al of two-fold serial dilutions of Mabs,
Fabs, sCD4 or polyclonal sera with 25 Al pseudovirus
suspension for 1 h at 4 -C. The virus–antibody mixtures were
then combined with 150 Al suspensions of 1–2  104 HOS
CD4+CCR5+ or HOS CD4+CXCR4+ cells in wells of 96-well,
white-walled, flat-bottomed tissue culture plates (Costar, Corn-
ing NY). The plates were incubated at 37 -C in 5% CO2 for 3
days then washed with phosphate-buffered saline and lysed for30 min with 15 Al of Luciferase Assay System cell lysis buffer
(Promega, Madison WI). Luciferase activity was read using a
MicroLumat Plus luminometer (Wallac, Gaithersburg MD).
Neutralization titers were determined based on luminescence,
and the endpoint was the last dilution of sera or other ligand at
which the mean results from the test samples were less than
50% of the non-neutralized control mean. The concentrations of
sera or Mab that resulted in 90% neutralization were always
two- to eight- and usually four-fold greater than those that
produced 50% neutralization. Neutralization assays for each
Env clone were carried out with each Mab in at least two
independent experiments. However, due to limited serum
volumes, serum neutralization assays were only done once in
most cases and twice in a few cases.
Construction of gp41 clones
To study the quasispecies variation within the 2F5/4E10
epitope regions, we used PBMC genomic DNA of BCN donors
14/00 and 24/00 to synthesize a 1.3 kb gp41 fragment. The outer
primers previously mentioned were used in the PCR, and the
inner primers were: sense (nt 7405–7426): 5V-GGACAGTT-
TAATACCACAGGATCC-3V (designed for 14/00) or 5V-
CTGGGAGTACAATAGCACTTGGGG-3V (designed for 24/
00) and antisense (nt 8795–8771): 5V-TTATAGCAAAGCC-
CTTTCTAAGCCC-3V.
The PCR products were gel purified and cloned into the
TOPO cloning vector (Invitrogen, Carlsbad, CA). We selected
10–16 gp41 clones from 14/00 and 24/00 and analyzed by
sequencing in both directions.
Construction of Env mutants
To study the effects of specific amino acid mutations, at
residues within or near the 2F5 epitope on neutralization
sensitivity, we introduced site-directed mutations into the Env
clones 14/00/4, 24/00/4, NYU1026 and NYU1423 using the
Quick Change mutagenesis kit (Stratagene, La Jolla, CA).
Mutations were verified by sequencing.
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